ABSTRACT
CONTEXT: A fixed-dose combination (FDC) of candesartan and rosuvastatin was recently developed for the treatment of cardiovascular disease and expected to enhance patient compliance. OBJECTIVE: This study was performed to compare the single-dose pharmacokinetic properties and tolerability of DP-R208 (candesartan and rosuvastatin FDC) to those of each component administered alone in healthy Korean male volunteers. MATERIALS AND METHODS: A total of 40 healthy Korean volunteers were enrolled in this randomized, open-label, single-dose, two-treatment, two-way crossover study. During each treatment period, subjects received the test formulation (FDC tablet containing candesartan and rosuvastatin) or reference formulation (co-administration of candesartan and rosuvastatin). Plasma samples were collected pre-dose and at 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24, and 48 hours post-dose. Safety and tolerability were assessed by the evaluation of adverse events (AEs), physical examinations, laboratory assessments, 12-lead electrocardiograms (ECGs), and vital sign measurements. RESULTS: The 90% confidence intervals (CIs) of the geometric least-square mean ratios of Cmax, AUClast, and AUCinf were 0.86 - 1.00, 0.92 - 1.04, and 0.92 - 1.03 for candesartan, and 0.88 - 1.06, 0.91 - 1.08, and 0.91 - 1.03 for rosuvastatin, respectively. All of the AEs were mild, and there was no significant difference in the incidence of AEs between the formulations. Furthermore, the pharmacokinetic properties of the test and reference formulations met the regulatory criteria for bioequivalence. Discussion and conclusion: Both formulations were safe and well tolerated, and no significant difference was observed in the safety assessments of the treatments.â©.
Subject(s)
Angiotensin II Type 1 Receptor Blockers/pharmacokinetics , Antihypertensive Agents/pharmacokinetics , Benzimidazoles/pharmacokinetics , Biphenyl Compounds/pharmacokinetics , Hydroxymethylglutaryl-CoA Reductase Inhibitors/pharmacokinetics , Rosuvastatin Calcium/pharmacokinetics , Tetrazoles/pharmacokinetics , Administration, Oral , Adult , Angiotensin II Type 1 Receptor Blockers/administration & dosage , Angiotensin II Type 1 Receptor Blockers/adverse effects , Angiotensin II Type 1 Receptor Blockers/blood , Antihypertensive Agents/administration & dosage , Antihypertensive Agents/adverse effects , Antihypertensive Agents/blood , Area Under Curve , Asian People , Benzimidazoles/administration & dosage , Benzimidazoles/adverse effects , Benzimidazoles/blood , Biphenyl Compounds/administration & dosage , Biphenyl Compounds/adverse effects , Biphenyl Compounds/blood , Cross-Over Studies , Drug Combinations , Half-Life , Healthy Volunteers , Humans , Hydroxymethylglutaryl-CoA Reductase Inhibitors/administration & dosage , Hydroxymethylglutaryl-CoA Reductase Inhibitors/adverse effects , Hydroxymethylglutaryl-CoA Reductase Inhibitors/blood , Male , Metabolic Clearance Rate , Middle Aged , Republic of Korea , Rosuvastatin Calcium/administration & dosage , Rosuvastatin Calcium/adverse effects , Rosuvastatin Calcium/blood , Tablets , Tetrazoles/administration & dosage , Tetrazoles/adverse effects , Tetrazoles/blood , Therapeutic Equivalency , Young AdultABSTRACT
The high sensitivity C-reactive protein (hsCRP) is known to be a sensitive predictor of coronary heart disease and type 2 diabetes. This study evaluated the association between the serum hsCRP and the components of metabolic syndrome (MS) and microvascular complications in type 2 diabetes. Two hundred and sixty-nine patients with type 2 diabetes were enrolled. All the subjects underwent measurement of MS and carotid intima-media thickness (IMT). The serum hsCRP concentrations and the 24 h urine albumin excretion amounts were measured. Ophthalmoscope examinations and nerve conduction velocity tests were performed to evaluate microvascular complications. The hsCRP was significantly higher in the patients with MS than in those without (p=0.019). The serum hsCRP was significantly correlated with all the components of MS. There were no differences between the serum hsCRP levels of those with and without retinopathy and neuropathy. The serum hsCRP was correlated with the 24 h urine albumin excretion amount. Serum hsCRP level has a significant correlation with MS and might be used as the future criteria of MS. Among microvascular complications, only diabetic nephropathy is associated with the serum hsCRP level. It suggests that the inflammatory process plays a role in nephropathy in type 2 diabetes.
Subject(s)
C-Reactive Protein/metabolism , Diabetes Mellitus, Type 2/blood , Diabetic Angiopathies/blood , Metabolic Syndrome/blood , Biomarkers/blood , Blood Pressure , Body Size , Carotid Arteries/pathology , Diabetes Mellitus, Type 2/pathology , Diabetic Angiopathies/pathology , Diabetic Nephropathies , Diabetic Neuropathies , Diabetic Retinopathy , Female , Humans , Lipids/blood , Male , Metabolic Syndrome/pathology , Middle Aged , Patient Selection , Tunica Intima/pathology , Tunica Media/pathologyABSTRACT
Thrombin, a crucial enzyme in the blood coagulation, has been a target for antithrombotic therapy. Orally active thrombin inhibitors would provide effective and safe prophylaxis for venous and arterial thrombosis. We conducted optimization of a highly efficacious benzamidine-based thrombin inhibitor LB30812 (3, K(i) = 3 pM) to improve oral bioavailability. Of a variety of arylamidines investigated at the P1 position, 2,5-thienylamidine effectively replaced the benzamidine without compromising the thrombin inhibitory potency and oral absorption. The sulfamide and sulfonamide derivatization at the N-terminal position in general afforded highly potent thrombin inhibitors but with moderate oral absorption, while the well-absorbable N-carbamate derivatives exhibited limited metabolic stability in S9 fractions. The present work culminated in the discovery of the N-carboxymethyl- and 2,5-thienylamidine-containing compound 22 that exhibits the most favorable profiles of anticoagulant and antithrombotic activities as well as oral bioavilability (K(i) = 15 pM; F = 43%, 42%, and 15% in rats, dogs, and monkeys, respectively). This compound on a gravimetric basis was shown to be more effective than a low molecular weight heparin, enoxaparin, in the venous thrombosis models of rat and rabbit. Compound 22 (LB30870) was therefore selected for further preclinical and clinical development.
Subject(s)
Amidines/chemical synthesis , Dipeptides/chemical synthesis , Protease Inhibitors/chemical synthesis , Sulfanilamides/chemical synthesis , Thrombin/antagonists & inhibitors , Administration, Oral , Amidines/pharmacokinetics , Amidines/pharmacology , Animals , Anticoagulants/chemical synthesis , Anticoagulants/pharmacokinetics , Anticoagulants/pharmacology , Biological Availability , Crystallography, X-Ray , Dipeptides/pharmacokinetics , Dipeptides/pharmacology , Dogs , Drug Stability , Fibrinolytic Agents/chemical synthesis , Fibrinolytic Agents/pharmacokinetics , Fibrinolytic Agents/pharmacology , Fluoroacetates , Haplorhini , Humans , In Vitro Techniques , Liver/drug effects , Liver/metabolism , Male , Models, Molecular , Protease Inhibitors/pharmacokinetics , Protease Inhibitors/pharmacology , Rabbits , Rats , Rats, Sprague-Dawley , Structure-Activity Relationship , Sulfanilamides/pharmacokinetics , Sulfanilamides/pharmacology , Venous Thrombosis/drug therapyABSTRACT
ETHNOPHARMACOLOGICAL RELEVANCE: Traditional Oriental medicine has utilized the barks of the stem and root of Ulmus davidiana var. japonica Nakai (UD) to treat inflammatory disorders. AIM OF THE STUDY: The purpose of the present study was to evaluate UD's anti-inflammatory and immune-modulating effects on a lipopolysaccharide (LPS)-stimulated macrophage cell line and small-intestinal lamina propria (LP) cells, respectively. MATERIALS AND METHODS: RAW 264.7 cells were stimulated with LPS in the presence of various concentrations of a UD water-soluble extract. Cell viability, nitric oxide (NO) production, and the level of inflammatory cytokines synthesis were measured. Among the mice receiving the UD water-soluble extract, changes in the LP cell populations and immunoglobulin (Ig)A production were evaluated. RESULTS: The UD water-soluble extract inhibited LPS-induced NO synthesis and inflammatory cytokine production in a RAW264.7 macrophage-like cell line. Small-intestinal LP cells isolated from mice that received the UD extract displayed a decrease in the side scatter of medium-to-high cells. Those LP cells isolated from the UD-treated mice also showed a marked decrease of intracellular IgA. However, UD administration had no apparent effect on the synthesis of systemic inflammatory cytokines. CONCLUSIONS: These results suggest that UD water-soluble extracts have anti-inflammatory properties and, as such, can be used to promote intestinal immune-homeostatic conditions.
Subject(s)
Anti-Inflammatory Agents/pharmacology , Immunologic Factors/pharmacology , Intestine, Small/drug effects , Macrophages/drug effects , Plant Extracts/pharmacology , Ulmus , Animals , Cell Line , Cytokines/blood , Female , Immunoglobulin A/immunology , Immunoglobulin G/immunology , Intestine, Small/immunology , Leukocytes/drug effects , Lipopolysaccharides , Macrophages/immunology , Mice , Mice, Inbred BALB C , Nitric Oxide/metabolismABSTRACT
BACKGROUND: Previous studies demonstrating the efficacy of insulin gene therapy have mostly involved use of adenoviral vectors or naked DNA to deliver the insulin gene. However, this procedure may not guarantee long-term insulin production. To improve the performance, we prepared recombinant adeno-associated viral vectors (rAAV) harboring the gene encoding a furin-modified human insulin under the cytomegalovirus (CMV) promoter [rAAV-hPPI(F12)]. METHODS: Streptozotocin (STZ)-induced diabetic Sprague-Dawley rats were used as a diabetic animal model. The levels of blood glucose, insulin, and HbA1c were measured to test the effect. An intraperitoneal glucose tolerance test was performed to test the capability of blood glucose disposal. Immunohistochemical staining and Northern blot analyses were performed to survey the expression pattern of the therapeutic insulin gene. RESULTS: STZ-induced diabetic Sprague-Dawley rats infused via the portal vein with rAAV-hPPI(F12) produced human insulin and after a 6-h fast were normoglycemic for over 90 days post-treatment, whereas diabetic rats treated with recombinant adenoviral vector harboring the hPPI(F12) gene [rAV-hPPI(F12)] were normoglycemic only for days 3 to 13 post-treatment. Insulin mRNA was detected mainly in the liver of the rAAV-hPPI(F12)-treated diabetic rats. The glucose tolerance capability of the rAAV-hPPI(F12)-treated diabetic rats was comparable to that of non-diabetic rats, even without injection of recombinant insulin. Furthermore, blood HbA1c concentrations in rAAV-hPPI(F12)-treated diabetic rats were reduced to almost the normal level. Importantly, studies of rAV or rAAV vector-dependent side effects on the targeted liver strongly suggested that only rAAV treatment caused no side effects. CONCLUSIONS: These results demonstrate that our rAAV-mediated in vivo insulin gene therapy provides safer maintenance of the insulin gene expression required for long-term and thus more effective blood glycemic control.
Subject(s)
Dependovirus/genetics , Diabetes Mellitus, Experimental/therapy , Gene Transfer Techniques , Genetic Therapy , Genetic Vectors , Insulin/genetics , Liver/metabolism , Animals , Animals, Genetically Modified , Blood Glucose/metabolism , Cytoskeletal Proteins/pharmacology , Diabetes Mellitus, Experimental/metabolism , Glucose Tolerance Test , Glycated Hemoglobin/metabolism , Insulin/metabolism , Male , Portal Vein , Proinsulin/metabolism , Pyrin , Rats , Rats, Sprague-Dawley , Safety , Treatment OutcomeABSTRACT
A series of noncovalent tripeptidic thrombin inhibitors incorporating amidrazone, amine and amidine functions at P1 was investigated. While the amidrazone and the amine series displayed limited oral absorption, the amidine series demonstrated generally good oral absorption and strong antithrombotic activity; the single-digit picomolar K(i) achieved from this series is among the best yet reported. The present work highlights the benzamidine compound 11f (LB30812) that exhibits excellent overall profiles of potency, oral absorption and antithrombotic efficacy.
Subject(s)
Amidines/chemistry , Amines/chemistry , Fibrinolytic Agents/chemical synthesis , Hemostatics/antagonists & inhibitors , Peptide Fragments/chemical synthesis , Serine Proteinase Inhibitors/chemical synthesis , Thrombin/antagonists & inhibitors , Administration, Oral , Amidines/metabolism , Amines/metabolism , Animals , Biological Availability , Dogs , Fibrinolytic Agents/pharmacokinetics , Fibrinolytic Agents/therapeutic use , Haplorhini , Models, Molecular , Molecular Structure , Peptide Fragments/pharmacokinetics , Peptide Fragments/therapeutic use , Rats , Serine Proteinase Inhibitors/pharmacology , Structure-Activity Relationship , Thrombin/metabolism , Trypsin/metabolismABSTRACT
To achieve the liver-directed expression in sufficient amounts of therapeutic genes for successful and safe gene therapy, natural liver-specific promoters can be used to direct the expression of therapeutic genes in the liver, whereas strong viral enhancers were used to obtain sufficient amounts of expressed therapeutic gene products. However, very often use of either the former or the latter does not guarantee both potent and liver-specific therapeutic gene expression. Here we conglomerate them and thus create a potent tissue-specific promoter by characterizing and using the liver-type pyruvate kinase proximal promoter (LPKPP) harboring its TATA box and a HNF-1alpha binding site. Alone it hardly activated its reporter gene expression in non-hepatocytes or hepatocytes. However, in the presence of the SV40 viral enhancer (SV40VE), which is active in multiple cell types, it was able to potently activate its reporter gene expression specifically in hepatocytes. The tissue-specific activation of the LPKPP by the viral enhancer was attributed to HNF-1alpha binding to the LPKPP. Taken together, these results support the idea that the constitutively active SV40VE could be used to activate the LPKPP in a tissue-specific manner in the presence of HNF-1alpha. To our knowledge, this is the first study to utilize HNF-1alpha and its binding site, in the context of the LPKPP, to generate a basal promoter that is transcriptionally activated potently in a tissue-specific manner by a viral enhancer that is active in multiple cell types.